The startup is the latest beneficiary of investors’ appetite for protein-degrading technology, which offers a way to reach ...

Cambridge biotech Nuclera has agreed a collaboration with Danaher company and international life sciences leader Cytiva – ...

US biotech royalty firm XOMA Royalty (Nasdaq: XOMA) has expanded its interest in mezagitamab, an anti-CD38 monoclonal antibody in Phase III development, through a deal worth up to $30 million with ...

InflaRx’s vilobelimab met the bar for futility in a Phase III trial for the rare skin disease pyoderma gangrenosum.

Enthera Pharmaceuticals ("Enthera"), a clinical-stage biotech company developing a first-in-class antibody therapeutic targeting the Insulin Growth Factor Binding Protein 3 (IGFBP3)/TMEM219 pathway ...

Ex-Ohio State football coach Jim Tressel is mulling a challenge the Trump-endorsed entrepreneur in next year’s governor’s race.

Rouzbeh Haghighat was serving on the board of Chinook Therapeutics at the time of the Novartis acquisition and, according to ...

Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced its participation in the ...

Researchers are developing an in vivo approach to engineer cancer-fighting immune cells, potentially making the powerful CAR ...

Biogen and City Therapeutics, a privately held developer of RNA-based “trigger molecules,” announced a partnership to develop ...

Zai Lab accelerates innovative drug launches in China through partnerships and expertise, targeting $1.5-$2B revenue by 2028.

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.